Immunogenicity and protective efficacy of inactivated equine influenza (H3N8) virus vaccine in murine model

Veterinary Microbiology

Volumn 210, Issue , 2017, Pages 188-196

  Pavulraj, Selvaraj ^a,c   Virmani, Nitin ^a   Bera, Bidhan Chandra ^a   Joshi, Alok ^b   Anand, Taruna ^a   Virmani, Meenakshi ^b   Singh, Rajendra ^c   Singh, Raj Kumar ^c   Tripathi, Bhupendra Nath ^a  

^a NATIONAL RESEARCH CENTRE ON EQUINES   (India)

^b LALA LAJPAT RAI UNIVERSITY OF VETERINARY AND ANIMAL SCIENCES   (India)

^c INDIAN VETERINARY RESEARCH INSTITUTE   (India)

Author keywords

Equine influenza; Mice model; Protective efficacy; Vaccine

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INACTIVATED EQUINE INFLUENZA VIRUS VACCINE; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; INACTIVATED VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EQUINE INFLUENZA (H3N8); HEMAGGLUTINATION INHIBITION TEST; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; INFECTION PREVENTION; INFLUENZA A VIRUS (H3N8); INFLUENZA VACCINATION; LIMIT OF QUANTITATION; MOUSE; NONHUMAN; SEROLOGY; VIRUS IMMUNITY; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; FEMALE; HORSE; HORSE DISEASE; IMMUNOLOGY; MALE; ORTHOMYXOVIRUS INFECTION; VACCINATION; VETERINARY; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HORSE DISEASES; HORSES; INFLUENZA A VIRUS, H3N8 SUBTYPE; INFLUENZA VACCINES; MALE; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION; VACCINES, INACTIVATED; VIRAL LOAD;

EID: 85030165329     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2017.08.013     Document Type: Article

References (22)

1. Baz, M., Paskel, M., Matsuoka, Y., Zengel, J., Cheng, X., Treanor, J.J., Jin, H., Subbarao, K., A live attenuated equine H3N8 influenza vaccine is highly immunogenic and efficacious in mice and ferrets. J. Virol. 89 (2015), 1652–1659.
2. Bouvier, N.M., Lowen, A.C., Animal models for influenza virus pathogenesis and transmission. Viruses 2 (2010), 1530–1563.
3. Crouch, C.F., Daly, J., Hannant, D., Wilkins, J., Francis, M.J., Immune responses and protective efficacy in ponies immunized with an equine influenza ISCOM vaccine containing an ‘American lineage’ H3N8 virus. Vaccine 23 (2004), 418–425.
4. Cullinane, A., Newton, J.R., Equine influenza −A global perspective. Vet. Microbiol. 167 (2013), 205–214.
5. European Agency for the Evaluation of Medicinal Produces (EMEA), Committee for Veterinary Medicinal Products (CVMP), Note for Guidance. Harmonization of Requirements for Equine Influenza Vaccines Specific Requirements for Substitution or Addition of a Strain or Strains. Document EMEA/CVMP/112/98- FINAL. 1998 (London, UK).
6. Heldens, J.G., Pouwels, H.G., Derks, C.G., Van de Zande, S.M., Hoeijmakers, M.J., Duration of immunity induced by an equine influenza and tetanus combination vaccine formulation adjuvanted with ISCOM-Matrix. Vaccine 28 (2010), 6989–6996.
7. Hirst, G.K., The agglutination of red cells by allantoic fluid of chick embryos infected with influenza virus. Science, 94, 1941, 22.
8. Landolt, A.G., Equine influenza virus. Vet. Clin. N. Am-Equine. 30 (2014), 507–522.
9. Lu, Z., Chambers, T.M., Boliar, S., Branscum, A.J., Sturgill, T.L., Timoney, P.J., Reedy, S.E., Tudor, L.R., Dubovi, E.J., Vickers, M.L., Sells, S., Balasuriya, U.B., Development and evaluation of one-Step TaqMan real-Time reverse transcription-PCR assays targeting nucleoprotein, matrix, and hemagglutinin genes of equine influenza virus. J. Clin. Microbiol. 47 (2009), 3907–3913.
10. Masanori, M., Yamanaka, T., Katayama, Y., Niwa, H., Oku, K., Matsumura, T., Oyamada, T., Time-related pathological changes in horses experimentally inoculated with equine influenza a virus. J. Equine. Sci. 23 (2012), 17–26.
11. Mumford, J.A., Wilson, H., Hannant, D., Jessett, D.M., Antigenicity and immunogenicity of equine influenza vaccines containing a Carbomer adjuvant. Epidemiol. Infect. 112 (1994), 421–437.
12. NRCE Annual Report, National Research Central on Equines, Annual Report 2009–2010., 2010 (pp. 21) http://nrce.gov.in/downloads/NRCE%20Annual%20Report%202009-10.pdf.
13. Newton, J.R., Lakhani, K.H., Wood, J.L.N., Baker, D.J., Risk factors for equine influenza serum antibody titres in young Thoroughbred racehorses given an inactivated vaccine. Prev. Vet. Med. 46 (2000), 129–141.
14. OIE Terrestrial manual, Chapter 2.5.7. Equine Influenza, 2016, 1–16.
15. Paillot, R., Kydd, J., Sindle, T., Hannant, D., Edlund-Toulemonde, C., Audonnet, J.C., Minke, J.M., Daly, J.M., Antibody and IFN-γ responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus. Vet. Immunol. Immunopathol. 112 (2006), 225–233.
16. Paillot, R., Prowse, L., Montesso, F., Stewart, B., Jordon, L., Newton, J.R., Gilkerson, J.R., Duration of equine influenza virus shedding and infectivity in immunized horses after experimental infection with EIV A/eq2/Richmond/1/07. Vet. Microbiol. 166 (2013), 22–34.
17. Paillot, R., A systematic review of recent advances in equine influenza vaccination. Vaccines 2 (2014), 797–831.
18. Pavulraj, S., Bera, B.C., Joshi, A., Anand, T., Virmani, M., Vaid, R.K., Shanmugasundaram, K., Gulati, B.R., Rajukumar, K., Singh, R., Misri, J., Singh, R.K., Tripathi, B.N., Virmani, N., Pathology of equine influenza virus (H3N8) in murine model. PLoS One, 10(11), 2015, e0143094.
19. Reed, L.J., Muench, H., A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27 (1938), 493–497.
20. Virmani, N., Bera, B.C., Singh, B.K., Shanmugasundaram, K., Gulati, B.R., Barua, S., Vaid, R.K., Gupta, A.K., Singh, R.K., Equine influenza outbreak in India (2008–09) Virus isolation, sero-epidemiology and phylogenetic analysis of HA gene. Vet. Microbiol. 143 (2010), 224–237.
21. Webster, R.G., Are equine 1 influenza viruses still present in horses?. Equine. Vet. J. 25 (1993), 537–538.
22. Wodal, W., Falkner, F.G., Kerschbaum, A., Gaiswinkler, C., Fritz, R., Kiermayr, S., Portsmouth, D., Savidis-Dacho, H., Coulibaly, S., Piskernik, C., Hohenadl, C., Howard, M.K., Kistner, O., Barrett, P.N., Kreil, T.R., A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate. Vaccine 30 (2012), 4625–4631.